Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders
- PMID: 40529079
- PMCID: PMC12169486
- DOI: 10.1021/acsmedchemlett.5c00288
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders
Abstract
Provided herein are novel ergolines as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders, and processes for preparing such compounds.
Published 2025 by American Chemical Society.
Similar articles
-
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13. ACS Med Chem Lett. 2025. PMID: 40104784
-
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9. ACS Med Chem Lett. 2024. PMID: 39811126
-
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529051
-
Dopamine agonists for preventing ovarian hyperstimulation syndrome.Cochrane Database Syst Rev. 2016 Nov 30;11(11):CD008605. doi: 10.1002/14651858.CD008605.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2021 Apr 14;4:CD008605. doi: 10.1002/14651858.CD008605.pub4. PMID: 27901279 Free PMC article. Updated.
-
Adverse effects of beta-agonists: are they clinically relevant?Am J Respir Med. 2003;2(4):287-97. doi: 10.1007/BF03256657. Am J Respir Med. 2003. PMID: 14719995
References
Publication types
LinkOut - more resources
Full Text Sources